NCT04106908 is a clinical trial of Eqwilate in VWD - Von Willebrand's Disease, sponsored by Octapharma.

Who is sponsoring NCT04106908?

NCT04106908 is sponsored by Octapharma.

What drugs are being tested in NCT04106908?

Interventions in NCT04106908: Eqwilate.

What condition does NCT04106908 study?

NCT04106908 studies VWD - Von Willebrand's Disease.

Is NCT04106908 still recruiting?

NCT04106908 is currently active, enrolled. Last updated 15 April 2025.

Last reviewed 2025-04-15 · How we verify

NCT04106908

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MOdalities of Use, effectiveNEss and TOlerability of Eqwilate® a Balanced combInatiON of VWF and FVIII in Von WillEbrand Patients in Real-life Conditions: the ONE-TO-ONE Study

Active, enrolled Last updated 15 April 2025

What this trial tests

trial testing Eqwilate in VWD - Von Willebrand's Disease in 38 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 November 2019

Primary endpoint
11 May 2024

1 November 2026

Quick facts

Lead sponsor	Octapharma
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	38
Start date	27 November 2019
Primary completion	11 May 2024
Estimated completion	1 November 2026
Sites	9 locations across France

Drugs / interventions tested

Eqwilate — full drug profile →

Conditions studied

VWD - Von Willebrand's Disease — all drugs for VWD - Von Willebrand's Disease →

Sponsor

Octapharma — full company profile →

Who can join

6 and older, any sex, with VWD - Von Willebrand's Disease.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Haemostatic Effectiveness of On-demand Treatment
Time frame: 12 months
Haemostatic Effectiveness of On-demand Treatment (excellent, good, moderate, none) none: severe uncontrolled bleeding or intensity of bleeding not changed (in case of non-severe bleeding episodes); moderate: moderate bleeding, or control of bleeding required additional product; good: slight oozing and adequate control of bleeding episode and did not require additional product; excellent: haemosta
Haemostatic Effectiveness of Perioperative Prophylaxis
Time frame: 12 months
Haemostatic Effectiveness of Perioperative Prophylaxis (excellent, good, moderate, none) none: severe uncontrolled bleeding or intensity of bleeding not changed (in case of non-severe bleeding episodes); moderate: moderate bleeding, or control of bleeding required additional product; good: slight oozing and adequate control of bleeding episode and did not require additional product; excellent: ha
Occurrence of Bleeding Episodes During Follow-Up
Time frame: 12 months
Occurrence of Bleeding Episodes During Follow-Up

Sponsor's own description

MOdalities of use, effectiveNEss and TOlerability of Eqwilate® a balanced combInatiON of VWF and FVIII in von WillEbrand patients in real-life conditions: the ONE-TO-ONE study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Octapharma trials

Trials by the same sponsor.

NCT06429787 — Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Antico · recruiting
NCT05523297 — Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery · Phase 3 · completed
NCT04918173 — Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery · Phase 3 · recruiting
NCT04953884 — Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age · Phase 3 · completed
NCT04508530 — Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04106908 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Octapharma
Last refreshed: 15 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04106908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing